245 related articles for article (PubMed ID: 24472478)
21. Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials.
Rugo HS; Roche H; Thomas E; Chung HC; Lerzo GL; Vasyutin I; Patel A; Vahdat L
Clin Breast Cancer; 2018 Dec; 18(6):489-497. PubMed ID: 30153978
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
Li T; Guo M; Gradishar WJ; Sparano JA; Perez EA; Wang M; Sledge GW
Breast Cancer Res Treat; 2012 Jul; 134(1):345-52. PubMed ID: 22547107
[TBL] [Abstract][Full Text] [Related]
23. Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer.
Castaneda CA; Gómez HL
Clin Breast Cancer; 2009 Nov; 9(4):E1-3. PubMed ID: 19933071
[TBL] [Abstract][Full Text] [Related]
24. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
[TBL] [Abstract][Full Text] [Related]
25. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Egerton N
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1005-12. PubMed ID: 20886213
[TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Reed SD; Li Y; Anstrom KJ; Schulman KA
J Clin Oncol; 2009 May; 27(13):2185-91. PubMed ID: 19332722
[TBL] [Abstract][Full Text] [Related]
27. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
Villanueva C; Awada A; Campone M; Machiels JP; Besse T; Magherini E; Dubin F; Semiond D; Pivot X
Eur J Cancer; 2011 May; 47(7):1037-45. PubMed ID: 21339064
[TBL] [Abstract][Full Text] [Related]
28. Ixabepilone, a new treatment option for metastatic breast cancer.
Toppmeyer DL; Goodin S
Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567
[TBL] [Abstract][Full Text] [Related]
29. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
Crown JP; Diéras V; Staroslawska E; Yardley DA; Bachelot T; Davidson N; Wildiers H; Fasching PA; Capitain O; Ramos M; Greil R; Cognetti F; Fountzilas G; Blasinska-Morawiec M; Liedtke C; Kreienberg R; Miller WH; Tassell V; Huang X; Paolini J; Kern KA; Romieu G
J Clin Oncol; 2013 Aug; 31(23):2870-8. PubMed ID: 23857972
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan.
Aogi K; Rai Y; Ito Y; Masuda N; Watanabe J; Horiguchi J; Tokudome T; Takashima S
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1427-33. PubMed ID: 23536163
[TBL] [Abstract][Full Text] [Related]
31. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Pallis AG; Boukovinas I; Ardavanis A; Varthalitis I; Malamos N; Georgoulias V; Mavroudis D
Ann Oncol; 2012 May; 23(5):1164-1169. PubMed ID: 21937705
[TBL] [Abstract][Full Text] [Related]
32. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
33. Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.
Wang HQ; Qian ZZ; Liu XM; Zhang HL; Li LF; Qiu LH; Hou Y; Zhou SY; Hao XS; Xie CH
Chin Med J (Engl); 2010 Nov; 123(22):3212-6. PubMed ID: 21163117
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
35. Ixabepilone for the treatment of breast cancer.
Alvarez RH; Valero V; Hortobagyi GN
Ann Med; 2011; 43(6):477-86. PubMed ID: 21585248
[TBL] [Abstract][Full Text] [Related]
36. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Clemons M; Joy AA; Abdulnabi R; Kotliar M; Lynch J; Jordaan JP; Iscoe N; Gelmon K
Breast Cancer Res Treat; 2010 Nov; 124(1):177-86. PubMed ID: 20814815
[TBL] [Abstract][Full Text] [Related]
37. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.
Zhang P; Tong Z; Tian F; Wang Y; Yang J; Li W; Di L; Liu W; Tang L; Qiu R; Xu B
J Hematol Oncol; 2016 Aug; 9(1):68. PubMed ID: 27516093
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
[TBL] [Abstract][Full Text] [Related]
40. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
Chan S; Romieu G; Huober J; Delozier T; Tubiana-Hulin M; Schneeweiss A; Lluch A; Llombart A; du Bois A; Kreienberg R; Mayordomo JI; Antón A; Harrison M; Jones A; Carrasco E; Vaury AT; Frimodt-Moller B; Fumoleau P
J Clin Oncol; 2009 Apr; 27(11):1753-60. PubMed ID: 19273714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
